Aspen Neuroscience Plans IPO of About 9.4 Million Shares at $15-$17

what happened

San Diego-based clinical-stage biotech Aspen Neuroscience is preparing an initial public offering. It intends to sell nearly 9.4 million shares at between $15 and $17 each. At the $16 midpoint, the company expects net proceeds of about $134.5 million, or roughly $155.4 million if underwriters exercise their option to buy an additional 1.41 million shares. Dow Jones Newswires reported the details.

Aspen is developing therapies for neurodegenerative diseases with high unmet medical need. The company said the proceeds, together with existing resources, will fund operations into the second half of 2028. After the offering, it would have nearly 30.5 million shares outstanding, assuming the option is exercised, for a market capitalization of around $488 million at the midpoint. The company has applied to list on the Nasdaq Global Select Market under the symbol ASPE.

why it matters

For markets, this is mainly a single deal in biotechnology: the offering is modest in size and has limited impact on broad indexes. Investors often read biotech IPOs as a gauge of appetite for risk assets, and as a check on how well a company is funded before its trial results arrive.

tags

instruments